Arrhythmias in Autoimmune Rheumatic Disease Save

Know-it-now

• Anti-Ro/SSA antibodies are a distinct, partly reversible arrhythmogenic mechanism (hERG and calcium channel blockade) — screen for QTc prolongation and AV block in patients positive for SSA antibodies.
• Atrial fibrillation (AF) is most common, except for systemic sclerosis (SSc) where  ventricular arrhythmias (VA predominate.  Ventricular arrhythmias  are more common with myocardial inflammation complicating acute pericarditis.
• SSc carries the highest cardiovascular risk among autoimmune diseases and is a common cause of SSc-related deaths.
• Cardiac magnetic resonance (CMR) detects fibrosis and inflammation, and should be considered especially in patients normal LVEF.
• Controlling systemic inflammation is itself an antiarrhythmic strategy. Yet, there are no RCTs addressing arrhythmia prevention.

A new review in the Journal of Cardiovascular Development and Disease (Tamirisa et al) synthesizes how systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc) have an increased risk of arrhythmias and sudden cardiac death (SCD) attributable to shared immune pathways. These facts substantiate the need for rheumatology-cardiology collaboration in disease management.

Mechanisms. Three overlapping pathways underlie  arrhythmias in autoimmune disorders. First, pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17) directly effects cardiomyocyte electrophysiology — TNF-α downregulates potassium currents and prolongs action potential duration, IL-1β triggers abnormal calcium release causing after-depolarizations, and IL-6 enhances L-type calcium current while impairing calcium reuptake. NLRP3 inflammasome activation compounds this via potassium current reduction and CaMKII oxidation. Second, autoantibodies exert direct electrophysiologic effects: anti-Ro/SSA antibodies inhibit hERG potassium channels (causing QT prolongation) and block L-type calcium channels in the AV node — a potentially reversible cause of adult heart block, in contrast to the irreversible fibrotic AV block seen in fetal congenital heart block. A population study of >17,000 anti-Ro-seropositive individuals found significantly elevated conduction (OR 1.44) and rhythm (OR 1.21) disturbances. Third, TGF-β1/NF-κB-driven fibrosis creates heterogeneous conduction zones and re-entrant substrate.

Disease-specific risks. In SLE, the 10-year risk of ventricular arrhythmia/SCD/ICD is nearly triple that of the general population; AV block occurs in 34–70% and may regress with disease control. RA carries twice the SCD risk of non-RA patients, with seropositive RA at higher AF risk than seronegative disease (aHR 1.63 vs. 1.37); tight disease control appears to reduce arrhythmic risk. SSc carries the highest cardiovascular hazard ratio (3.59) among the three, with VA (not AF) predominating — premature ventricular contractions in up to 67%, SCD in 5–21%, and conduction disease in 25–75%, driven by patchy replacement fibrosis from microvascular injury.

Diagnostics and management. Cardiac MRI with T1/T2 mapping and late gadolinium enhancement can detect inflammation and fibrosis even with preserved ejection fraction, outperforming standard echocardiography and enabling earlier intervention; endomyocardial biopsy remains limited by sampling error given the patchy, often subepicardial distribution of disease. Management pairs standard antiarrhythmic/device therapy with aggressive immunosuppression targeting the inflammatory substrate — with special caution regarding vasoconstrictive antiarrhythmics in SSc patients with Raynaud's phenomenon.